Job Trends
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.
THE LATEST
Bristol Myers Squibb and Exelixis announced new analysis from the Phase III CheckMate -9ER clinical trial.
Here’s a recap of companies announcing facility expansions this past month and life sciences job creations across the nation.
Bristol Myers picked up the therapy when it acquired Celgene in 2019 for $74 billion.
South Africa has delayed the distribution of the AstraZeneca-University of Oxford COVID-19 vaccine after data suggested it “provides minimal protection” against mild disease from the South African variant.
Pfizer struck a collaboration and licensing agreement with Belgium-based Imcyse for a rheumatoid arthritis program, which is based on that company’s Imotope technology.
Merck Chief Executive Officer Kenneth C. Frazier is stepping down from his role atop the helm of the pharma giant on June 30 after nearly 30 years with the company.
As the therapy “did not achieve proof-of-concept” and failed to provide benefit in this study, the development of the drug has been discontinued.
Amgen released its fourth-quarter and full-year 2020 results today and although there was good news financially, there was also news of five cancer programs that have either been halted or abandoned.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
Although designed for two doses, primary analysis of AstraZeneca and the University of Oxford’s Phase III data for its COVID-19 vaccine found it to have 76% efficacy after the first dose.